Glutamate receptors and Parkinson's disease: Opportunities for intervention

Drugs and Aging

Volumn 20, Issue 5, 2003, Pages 377-397

  Marino, Michael J ^a   Valenti, Ornella ^a   Conn, P Jeffrey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BASAL GANGLION; BRAIN FUNCTION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRIATE CORTEX; SUBSTANTIA NIGRA;

ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PARKINSON DISEASE; RECEPTORS, GLUTAMATE;

EID: 0037273830     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320050-00006     Document Type: Review

References (227)

1. Lang AE, Lozano AM. Parkinson's Disease - first of two parts. N Engl J Med 1998; 339 (15): 1044-53
2. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334 (2): 71-6
3. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938; 48: 387-476
4. Erhinger H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960; 38: 1236-9
5. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58 (90001): 19S-32
6. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13 (7): 281-5
7. Wichmann T, DeLong MR. Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am 1998; 9 (2): 223-36
8. Hollerman JR, Grace AA. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 1992; 590 (1-2): 291-9
9. Bergman H, Wichmann T, Karmon B, et al. The primate subthalamic nucleus: II. neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72 (2): 507-20
10. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996; 72 (1): 105-15
11. Benazzouz A, Breit S, Koudsie A, et al. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17 Suppl. 3: S145-9
12. Rodriguez-Oroz MC, Rodriguez M, Guridi J, et al. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 2001; 124 (Pt 9): 1777-90
13. Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 2001; 16 (1): 72-8
14. Guridi J, Obeso JA. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 2001; 124 (Pt 1): 5-19
15. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76 (1): 53-61
16. Bakay RA, DeLong MR, Vitek JL. Posteroventral pallidotomy for Parkinson's disease. J Neurosurg 1992; 77 (3): 487-8
17. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40 (3): 355-66
18. Vitek JL, Bakay RA, Hashimoto T, et al. Microelectrodeguided pallidotomy: technical approach and its application in medically intractable Parkinson's disease. J Neurosurg 1998; 88 (6): 1027-43
19. Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345 (8942): 91-5
20. Deep-Brain Stimulation For Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345 (13): 956-63
21. Blandini F, Nappi G, Tassorelli C, et al. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000; 62 (1): 63-88
22. Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res 1998; 116: 153-70
23. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37: 205-37
24. Dingledine R, Borges K, Bowie D, et al. The glutamate receptor ion channels. Pharmacol Rev 1999; 51 (1): 7-61
25. Rouse ST, Marino MJ, Bradley SR, et al. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 2000; 88 (3): 427-35
26. Smith Y, Charara A, Paquet M, et al. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia. J Chem Neuroanat 2001; 22 (1-2): 13-42
27. Malenka RC, Nicoll RA. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci 1993; 16 (12): 521-7
28. Morris RG, Davis S, Butcher SP. Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Philos Trans R Soc Lond B Biol Sci 1990; 329 (1253): 187-204
29. Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988; 11: 61-80
30. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 2000; 32 (2-3): 476-509
31. Scheetz AJ, Constantine-Paton M. Modulation of NMDA receptor function: implications for vertebrate neural development. FASEB J 1994; 8 (10): 745-52
32. Mody I, MacDonald JF. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol Sci 1995; 16 (10): 356-9
33. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor: still lethal after eight years. Trends Neurosci 1995; 18 (2): 57-8
34. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325 (6104): 529-31
35. Johnson JW, Ascher P. Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons. J Physiol 1992; 455: 339-65
36. Laube B, Hirai H, Sturgess M, et al. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997; 18 (3): 493-503
37. Anson LC, Chen PE, Wyllie DJ, et al. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci 1998; 18 (2): 581-9
38. Kuryatov A, Laube B, Betz H, et al. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron 1994; 12 (6): 1291-300
39. Wafford KA, Kathoria M, Bain CJ, et al. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol Pharmacol 1995; 47 (2): 374-80
40. Hirai H, Kitsch J, Laube B, et al. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci U S A 1996; 93 (12): 6031-6
41. Williams K, Chao J, Kashiwagi K, et al. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit. Mol Pharmacol 1996; 50 (4): 701-8
42. Wood MW, VanDongen HM, VanDongen AM. An alanine residue in the M3-M4 linker lines the glycine binding pocket of the N-methyl-D-aspartate receptor. J Biol Chem 1997; 272 (6): 3532-7
43. Ascher P, Bregestovski P, Nowak L. N-methyl-D-aspartate-activated channels of mouse central neurones in magnesium-free solutions. J Physiol 1988; 399: 207-26
44. Mayer ML, Westbrook GL. Permeation and block of N-methyl-D-aspartic acid receptor channels by divalent cations in mouse cultured central neurones. J Physiol 1987; 394: 501-27
45. Mayer ML, Westbrook GL. The action of N-methyl-D-aspartic acid on mouse spinal neurones in culture. J Physiol 1985; 361: 65-90
46. Ascher P, Nowak L. The role of divalent cations in the N-methyl-D-aspartate responses of mouse central neurones in culture. J Physiol 1988; 399: 247-66
47. Nowak L, Bregestovski P, Ascher P, et al. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984; 307 (5950): 462-5
48. Tsien JZ. Linking Hebb's coincidence-detection to memory formation. Curr Opin Neurobiol 2000; 10 (2): 266-73
49. Seeburg PH, Burnashev N, Kohr G, et al. The NMDA receptor channel: molecular design of a coincidence detector. Recent Prog Horm Res 1995; 50: 19-34
50. Pisani A, Calabresi P, Centonze D, et al. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997; 120 (6): 1007-14
51. Gotz T, Kraushaar U, Geiger J, et al. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. J Neurosci 1997; 17 (1): 204-15
52. Awad H, Hubert GW, Smith Y, et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000; 20 (21): 7871-9
53. Marino MJ, Hubert GW, Smith Y, et al. Functional roles of group I metabotropic glutamate receptors in the substantia nigra pars reticulata [abstract]. Soc Neurosci 2000; 30 (16): 740
54. Starr MS. Antiparkinsonian actions of glutamate antagonists, alone and with LEVODOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm Park Dis Dement Sect 1995; 10 (2-3): 141-85
55. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 1993; 44 (4): 851-9
56. Avenet P, Leonardon J, Besnard F, et al. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes. Neurosci Lett 1997; 223 (2): 133-6
57. Gallagher MJ, Huang H, Pritchett DB, et al. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 1996; 271 (16): 9603-11
58. Menniti F, Chenard B, Collins M, et al. CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 1997; 331 (2-3): 117-26
59. Chenard BL, Bordner J, Butler TW, et al. (1S,2S)-1- (4-hydroxyphenyl)-2- (4-hydroxy-4-phenylpiperidino)- 1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 1995; 38 (16): 3138-45
60. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166 (3): 591-2
61. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104
62. Klockgether T, Jacobsen P, Loschmann PA, et al. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 1993; 5 (2): 101-6
63. Parsons CG, Hartmann S, Spielmanns P. Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. Neuropharmacology 1998; 37 (6): 719-27
64. Kornhuber J, Herr B, Thome J, et al. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 1995; 46: 131-7
65. Jackisch R, Kruchen A, Sauermann W, et al. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 1994; 264 (2): 207-11
66. Steece-Collier K, Chambers LK, Jaw-Tsai SS, et al. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 2000; 163 (1): 239-43
67. Bubser M, Zadow B, Kronthaler UO, et al. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 1997; 355 (6): 767-73
68. Kaur S, Ozer H, Starr M. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur J Pharmacol 1997; 332 (2): 153-60
69. McAllister KH. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur J Pharmacol 1996; 314 (3): 307-11
70. Moore NA, Blackman A, Awere S, et al. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur J Pharmacol 1993; 237 (1): 1-7
71. Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol 1999; 155 (1): 42-8
72. Kaur S, Starr MS. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur J Pharmacol 1995; 280 (2): 159-66
73. Ossowska K, Lorenc-Koci E, Wolfarth S. Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J Neural Transm Park Dis Dement Sect 1994; 7 (2): 143-52
74. Skuza G, Rogoz Z, Quack G, et al. Memantine, amantadine, and L-deprenyl potentiate the action of levodopa in monoamine-depleted rats. J Neural Transm Gen Sect 1994; 98 (1): 57-67
75. Greenberg DA. Glutamate and Parkinson's disease. Ann Neurol 1994; 35 (6): 639
76. Carlsson M, Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 1989; 77 (1): 65-71
77. Stauch-Slusher B, Rissolo KC, Jackson PF, et al. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J Neural Transm Gen Sect 1994; 97 (3): 175-85
78. Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease: comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology 1999; 38 (1): 109-19
79. Kretschmer BD, Zadow B, Volz TL, et al. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J Neural Transm Gen Sect 1992; 87 (1): 23-35
80. Kretschmer BD, Koch M. Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology 1997; 130 (2): 131-8
81. Mokry J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol Res 1995; 44 (3): 143-50
82. Klockgether T, Wullner U, Steinbach JP, et al. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 1996; 301 (1-3): 67-73
83. St Pierre JA, Bedard PJ. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine. Eur J Pharmacol 1995; 272 (2-3): 123-9
84. Loschmann PA, Wullner U, Heneka MT, et al. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse 1997; 26 (4): 381-91
85. Marin C, Papa S, Engber TM, et al. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996; 736 (1-2): 202-5
86. Engber TM, Papa SM, Boldry RC, et al. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994; 5 (18): 2586-8
87. Schmidt WJ, Kretschmer BD. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 1997; 21 (4): 381-92
88. Di Chiara G, Morelli M, Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 1994; 17 (6): 228-33
89. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13 (7): 272-6
90. Morelli M, Fenu S, Pinna A, et al. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 1992; 260 (1): 402-8
91. Morelli M, Di Chiara G. MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 1990; 182 (3): 611-2
92. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989; 75 (3): 221-6
93. Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000; 57 (2): 342-52
94. Dunah AW, Standaert DG. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 2001; 21 (15): 5546-58
95. Ganguly A, Keefe KA. Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience 2001; 103 (2): 405-12
96. Meshul CK, Emre N, Nakamura CM, et al. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999; 88 (1): 1-16
97. Graham WC, Robertson RG, Sambrook MA, et al. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 1990; 47 (18): L91-7
98. Crossman AR, Peggs D, Boyce S, et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 1989; 28 (11): 1271-3
99. Blanchet PJ, Konitsiotis S, Whittemore ER, et al. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999; 290 (3): 1034-40
100. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994; 35 (6): 655-61
101. Loschmann PA, Lange KW, Kunow M, et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with Levodopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991; 3 (3): 203-13
102. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996; 39 (5): 574-8
103. Avenet P, Leonardon J, Besnard F, et al. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur J Pharmacol 1996; 296 (2): 209-13
104. Kuppenbender KD, Standaert DG, Feuerstein TJ, et al. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol 2000; 419 (4): 407-21
105. Kosinski CM, Standaert DG, Counihan TJ, et al. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J Comp Neurol 1998; 390 (1): 63-74
106. Schito AM, Pizzuti A, Di Maria E, et al. mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit. Neurosci Lett 1997; 239 (1): 49-53
107. Jin DH, Jung YW, Ko BH, et al. Immunoblot analyses on the differential distribution of NR2A and NR2B subunits in the adult rat brain. Mol Cells 1997; 7 (6): 749-54
108. Nash JE, Fox SH, Henry B, et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000; 165 (1): 136-42
109. Mitchell IJ, Carroll CB. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 1997; 21 (4): 469-75
110. Montastruc JL, Rascol O, Senard JM, et al. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55 (7): 630-1
111. Schwab RS, England Jr AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208 (7): 1168-70
112. Fischer PA, Jacobi P, Schneider E, et al. Effects of intravenous administration of memantine in parkinsonian patients. Arzneimittelforschung 1977; 27 (7): 1487-9
113. Kornhuber J, Bormann J, Retz W, et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166 (3): 589-90
114. Kornhuber J, Bormann J, Hubers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206 (4): 297-300
115. Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34 (7): 713-21
116. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16 (3): 515-20
117. Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23 (2): 82-5
118. Verhagen-Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50 (5): 1323-6
119. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56 (11): 1383-6
120. Merello M, Nouzeilles MI, Cammarota A, et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22 (5): 273-6
121. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4: 277-82
122. Schneider E, Fischer PA, Clemens R, et al. Wirkungen oraler Memantin-Gaben auf die Parkinson-Symptomatik. Ergebnisse einer placebo-kontrollierten Multicenter-Studie. Dtsch Med Wochenschr 1984; 109 (25): 987-90
123. Fischer PA, Jacobi P, Schneider E, et al. Die Wirkung intravenoser Gaben von Memantin bei Parkinson-Kranken. Arzneimittelforschung 1977; 27 (7): 1487-9
124. Malsch U, Bliesath H, Bother K, et al. Monotherapie der Parkinsonschen Erkrankung mit Budipin. Ein randomisierter Doppelblindvergleich mit Amantadin. Fortschr Neurol Psychiatr 2001; 69 (2): 86-9
125. Spieker S, Loschmann PA, Klockgether T. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov Disord 1999; 14 (3): 517-9
126. Jellinger K, Bliesath H. Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J Neurol 1987; 234 (5): 280-2
127. Verhagen-Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998; 51 (1): 203-6
128. Verhagen-Metman L, Blanchet PJ, van den Munckhof P, et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998; 13 (3): 414-7
129. Blanchet PJ, Metman LV, Mouradian MM, et al. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996; 11 (5): 580-1
130. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996; 11 (3): 273-7
131. Richens A, Mawer G, Crawford P, et al. A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy. Seizure 2000; 9 (8): 537-43
132. Dyker AG, Lees KR. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 1999; 30 (9): 1796-801
133. Palmer GC, Murray RJ, Wilson TC, et al. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 1992; 12 (1): 9-20
134. Clarke CE, Cooper JA, Holdich TA. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin Neuropharmacol 2001; 24 (3): 133-8
135. Parkinson-Study-Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD: Parkinson Study Group. Neurology 2000; 54 (8): 1583-8
136. Shoulson I, Penney J, McDermott M, et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001; 56 (4): 455-62
137. Parkinson-Study-Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001; 58 (10): 1660-8
138. Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50 (4): 597-664
139. Giuffra ME, Sethy VH, Davis TL, et al. Milacemide therapy for Parkinson's disease. Mov Disord 1993; 8 (1): 47-50
140. Jonas P, Racca C, Sakmann B, et al. Differences in Ca2+ permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression. Neuron 1994; 12 (6): 1281-9
141. Burnashev N, Monyer H, Seeburg PH, et al. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 1992; 8 (1): 189-98
142. Muller T, Moiler T, Berger T, et al. Calcium entry through kainate receptors and resulting potassium-channel blockade in Bergmann glial cells. Science 1992; 256 (5063): 1563-6
143. Hollmann M, Hartley M, Heinemann S. Ca2+ permeability of KA-AMPA: gated glutamate receptor channels depends on subunit composition. Science 1991; 252 (5007): 851-3
144. Rueter SM, Burns CM, Coode SA, et al. Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science 1995; 267 (5203): 1491-4
145. Washburn MS, Dingledine R. Block of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by polyamines and polyamine toxins. J Pharmacol Exp Ther 1996; 278 (2): 669-78
146. Swanson GT, Feldmeyer D, Kaneda M, et al. Effect of RNA editing and subunit co-assembly single-channel properties of recombinant kalnate receptors. J Physiol 1996; 492 (Pt 1): 129-42
147. Herlitze S, Raditsch M, Ruppersberg JP, et al. Argiotoxin detects molecular differences in AMPA receptor channels. Neuron 1993; 10 (6): 1131-40
148. Brackley PT, Bell DR, Choi SK, et al. Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins. J Pharmacol Exp Ther 1993; 266 (3): 1573-80
149. Tanaka H, Grooms SY, Bennett MV, et al. The AMPAR subunit GluR2: still front and center-stage. Brain Res 2000; 886 (1-2): 190-207
150. Myers SJ, Dingledine R, Borges K. Genetic regulation of glutamate receptor ion channels. Annu Rev Pharmacol Toxicol 1999; 39: 221-41
151. Pellegrini-Giampietro DE, Gorter JA, Bennett MV, et al. The GluR2 (GluR-B) hypothesis: Ca (2+)-permeable AMPA receptors in neurological disorders. Trends Neurosci 1997; 20 (10): 464-70
152. Betarbet R, Porter RH, Greenamyre JT. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J Neurochem 2000; 74 (3): 1166-74
153. He Y, Lee T, Leong SK. Effect of 6-OHDA injection on the AMPA glutamate receptor subunits in the substantia nigra of Sprague-Dawley rats. Neurosci Lett 1998; 241 (1): 1-4
154. Bernard V, Gardiol A, Faucheux B, et al. Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion. J Comp Neurol 1996; 368 (4): 553-68
155. Arnt J. Turning behaviour and catalepsy after injection of excitatory amino acids into rat substantia nigra. Neurosci Lett 1981; 23 (3): 337-42
156. Turski W, Turski L, Czuczwar SJ, et al. (RS)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: wet dog shakes, catalepsy and body temperature changes in rats. Pharmacol Biochem Behav 1981; 15 (4): 545-9
157. Wachtel H, Kunow M, Loschmann PA. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci Lett 1992; 142 (2): 179-82
158. Loschmann PA, Kunow M, Wachtel H. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease. J Neural Transm Suppl 1992; 38: 55-64
159. Zadow B, Schmidt WJ. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol 1994; 349 (1): 61-5
160. Papa SM, Engber TM, Boldry RC, et al. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol 1993; 232 (2-3): 247-53
161. Maj J, Rogoz Z, Skuza G, et al. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Pol J Pharmacol 1995; 47 (6): 501-7
162. Konitsiotis S, Blanchet PJ, Verhagen L, et al. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000; 54 (8): 1589-95
163. Marin C, Jimenez A, Bonastre M, et al. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 2000; 36 (4): 267-74
164. Matin C, Jimenez A, Bonastre M, et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 2001; 42 (1): 40-7
165. Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991; 30 (5): 717-23
166. Luquin MR, Obeso JA, Laguna J, et al. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 1993; 235 (2-3): 297-300
167. Rodriguez-Moreno A, Lopez-Garcia JC, Lerma J. Two populations of kainate receptors with separate signaling mechanisms in hippocampal interneurons. Proc Natl Acad Sci U S A 2000; 97 (3): 1293-8
168. Rodriguez-Moreno A, Lerma J. Kainate receptor modulation of GABA release involves a metabotropic function. Neuron 1998; 20(6): 1211-8
169. Rodriguez-Moreno A, Herreras O, Lerma J. Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus. Neuron 1997; 19 (4): 893-901
170. Charara A, Blankstein E, Smith Y. Presynaptic kainate receptors in the monkey striatum. Neuroscience 1999; 91 (4): 1195-200
171. Kieval JZ, Hubert GW, Charara A, et al. Subcellular and subsynaptic localization of presynaptic and postsynaptic kainate receptor subunits in the monkey striatum. J Neurosci 2001; 21 (22): 8746-57
172. Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2001; 2 (5): 657-62
173. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23 (7): 298-304
174. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000; 7 (4): 240-50
175. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36 (26): 2503-8
176. Yoshino H, Nakagawa-Hattori Y, Kondo T, et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4 (1): 27-34
177. Krige D, Carroll MT, Cooper JM, et al. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 1992; 32 (6): 782-8
178. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54 (3): 823-7
179. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26 (6): 719-23
180. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81 (3): 163-221
181. Massieu L, Garcia O. The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Neurobiology (Bp) 1998; 6 (1): 99-108
182. Ikonomidou C, Tarski L. Excitotoxicity and neurodegenerative diseases. Curr Opin Neurol 1995; 8 (6): 487-97
183. Beal MF. Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol 1992; 2 (5): 657-62
184. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42 (4): 733-8
185. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993; 16 (4): 125-31
186. Erecinska M, Dagani F. Relationships between the neuronal sodium/potassium pump and energy metabolism: Effects of K+, Na+, and adenosine triphosphate in isolated brain synaptosomes. J Gen Physiol 1990; 95 (4): 591-616
187. Novelli A, Reilly JA, Lysko PG, et al. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451 (1-2): 205-12
188. Kita H, Kitai ST. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 1987; 260 (3): 435-52
189. Smith ID, Grace AA. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 1992; 12 (4): 287-303
190. Iribe Y, Moore K, Pang KC, et al. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J Neurophysiol 1999; 82 (2): 925-33
191. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998; 44 (3 Suppl. 1): S175-88
192. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996; 8 (7): 1408-14
193. Turski L, Bressler K, Rettig KJ, et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349 (6308): 414-8
194. Sonsalla PK, Zeevalk GD, Manzino L, et al. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 1992; 58 (5): 1979-82
195. Lange KW, Loschmann PA, Sofic E, et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol 1993; 348 (6): 586-92
196. Zuddas A, Oberto G, Vaglini F, et al. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992; 59 (2): 733-9
197. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 2001; 49 (4): 525-9
198. De Blasi A, Conn PJ, Pin J, et al. Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol Sci 2001; 22 (3): 114-20
199. Alagarsamy S, Sorensen SD, Conn PJ. Coordinate regulation of metabotropic glutamate receptors. Curr Opin Neurobiol 2001; 11 (3): 357-62
200. Pisani A, Bernardi G, Bonsi P, et al. Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids 2000; 19 (1): 119-29
201. Calabresi P, Centonze D, Pisani A, et al. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp Neurol 1999; 158 (1): 97-108
202. Sacaan AI, Monn JA, Schoepp DD. Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat. J Pharmacol Exp Ther 1991; 259 (3): 1366-70
203. Sacaan AI, Bymaster FP, Schoepp DD. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J Neurochem 1992; 59 (1): 245-51
204. Kearney JA, Frey KA, Albin RL. Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study. J Neurosci 1997; 17 (11): 4415-25
205. Kaatz KW, Albin RL. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and Fos immunohistochemical study. Neuroscience 1995; 66 (1): 55-65
206. Calabresi P, Mercuri NB, Bernardi G. Activation of quisqualate metabotropic receptors reduces glutamate and GABA-mediated synaptic potentials in the rat striatum. Neurosci Lett 1992; 139 (1): 41-4
207. East SJ, Hill MP, Brotchie JM. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. Ear J Pharmacol 1995; 277 (1): 117-21
208. Lovinger DM, McCool BA. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 1995; 73 (3): 1076-83
209. Lombardi G, Alesiani M, Leonardi P, et al. Pharmacological characterization of the metabotropic glutamate receptor inhibiting D-[3H]-aspartate output in rat striatum. Br J Pharmacol 1993; 110 (4): 1407-12
210. Pisani A, Calabresi P, Centonze D, et al. Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. Neuropharmacology 1997; 36 (6): 845-51
211. Stefani A, Pisani A, Mercuri NB, et al. Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. J Neurosci 1994; 14 (11 Pt 1): 6734-43
212. Poisik OV, Mannaioni G, Traynelis S, et al. Distinct functional roles of the metabolic glutamate receptors 1 and 5 in the rat globus pallidus. J Neurosci 2003; 23 (1): 122-30
213. Beurrier C, Congar P, Bioulac B, et al. Subthalamic nucleus neurons switch from single-spike activity to burst- firing mode. J Neurosci 1999; 19 (2): 599-609
214. Awad-Granko H, Conn PJ. Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus. Neuropharmacology 2001; 41 (1): 32-41
215. Kearney JA, Albin RL. Intrasubthalamic nucleus metabotropic glutamate receptor activation: a behavioral, Fos immunohistochemical and [14C]2-deoxyglucose autoradiographic study. Neuroscience 2000; 95 (2): 409-16
216. Bradley SR, Marino MJ, Wittmann M, et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 2000; 20 (9): 3085-94
217. Wittmann M, Marino MJ, Bradley SR, et al. Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. J Neurophysiol 2001; 85 (5): 1960-8
218. Marino MJ, Wittman M, Bradley SR, et al. Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. J Neurosci 2001; 21 (18): 7001-12
219. Hubert GW, Paquet M, Smith Y. Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra. J Neurosci 2001; 21 (6): 1838-47
220. Magill PJ, Bolam JP, Bevan MD. Relationship of activity in the subthalamic nucleus-globus pallidus network to cortical electroencephalogram. J Neurosci 2000; 20 (2): 820-33
221. Spooren WP, Gasparini F, Bergmann R, et al. Effects of the prototypical mGlu (5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 2000; 406 (3): 403-10
222. Ossowska K, Konieczny J, Wolfarth S, et al. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001; 41 (4): 413-20
223. Breysse N, Baunez C, Spooren W, et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002; 22 (13): 5669-78
224. Hill MP, McGuire SG, Crossman AR, et al. The mGluR5 receptor antagonist SIB-1830 reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease [abstract]. Soc Neurosci 2001; 25 (16): 200
225. Testa CM, Standaert DG, Young AB, et al. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 1994; 14 (5 Pt 2): 3005-18
226. Konieczny J, Ossowska K, Wolfarth S, et al. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (4): 500-2
227. Dawson L, Chadha A, Megalou M, et al. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 2000; 129 (3): 541-6